CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ...

Osimertinib (Tagrisso) has a strong foothold as first-line therapy for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but resistance to the third-generation EGFR tyrosine ...

Source Reference: Wang VE, Gainor JF "Osimertinib in patients with non-small cell lung cancer and uncommon EGFR mutations -- chasing unicorns?" JAMA Oncol 2023; DOI: 10.1001/jamaoncol.2023.5004.

First-line osimertinib improved OS compared with standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors among patients with previously untreated advanced EGFR-mutated non ...

Osimertinib, sold under the brand name Tagrisso, is available to patients with Stage 1B-3A lung cancer who have a certain genetic mutation and have had surgery to remove cancerous tumors.

TAGRISSO® (osimertinib) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to inhibit both EGFR sensitizing and EGFR T790M ...

Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib ...

At 12 months, 74% (95% CI, 65-80) of patients treated with osimertinib were alive and progression free compared with 22% (95% CI, 13-32) of those who received placebo.

Osimertinib improved progression-free survival by 54%. This subset analysis included the 322 Asian patients in the FLAURA trial, of whom 46 were Chinese, 120 were Japanese, and 156 were from other ...

Credit: Getty Images. Osimertinib, a kinase inhibitor, is currently marketed under the brand name Tagrisso. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental ...

The third-generation EGFR-TKI osimertinib more than doubles progression-free survival in NSCLC, making it the standard of care in T790M-positive lung cancer, say experts.

Osimertinib is the first tumor drug approved for locally advanced or metastatic non-small cell lung cancer with positive EGFR T790M mutation in China. In March 2021, the application for the third ...